Entity

Time filter

Source Type

San Francisco, CA, United States

The present invention relates to novel compounds capable of modulating the stability and/or activity of hypoxia inducible factor (HIF).


Patent
FibroGen | Date: 2015-09-21

The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoictin-associated conditions. The cyanoisoquinoline compounds of the invention have the following structure:


The present invention relates to novel compounds according to Formula I or II, methods, and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF). Formula (I) or (II).


Patent
FibroGen | Date: 2014-02-14

The present invention provides methods and medicaments for reducing blood pressure. Methods and medicaments for treating or preventing hypertension are also provided.


Patent
FibroGen | Date: 2014-10-21

The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.

Discover hidden collaborations